Oliveira M, Rugo HS, Howell SJ, Dalenc F, et al. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2024;25:1231-1244.
PMID: 39214106